Display options
Cite
Wu LR, Yu HL, Jiang N, et al. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study. Oncotarget. 2017;8(44):76807-76815doi: 10.18632/oncotarget.20014.
Wu, L. R., Yu, H. L., Jiang, N., Jiang, X. S., Zong, D., Wen, J., Huang, L., Xie, P., Chen, W., Wang, T. T., Gu, D. Y., Yan, P. W., Yin, L., & He, X. (2017). Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study. Oncotarget, 8(44), 76807-76815. https://doi.org/10.18632/oncotarget.20014
Wu, Li-Rong, et al. "Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study." Oncotarget vol. 8,44 (2017): 76807-76815. doi: https://doi.org/10.18632/oncotarget.20014
Wu LR, Yu HL, Jiang N, Jiang XS, Zong D, Wen J, Huang L, Xie P, Chen W, Wang TT, Gu DY, Yan PW, Yin L, He X. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study. Oncotarget. 2017 Aug 07;8(44):76807-76815. doi: 10.18632/oncotarget.20014. eCollection 2017 Sep 29. PMID: 29100350; PMCID: PMC5652744.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Aug 07;8(44):76807-76815. doi: 10.18632/oncotarget.20014. eCollection 2017 Sep 29.

Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study.

Oncotarget

Li-Rong Wu, Hong-Liang Yu, Ning Jiang, Xue-Song Jiang, Dan Zong, Jing Wen, Lei Huang, Peng Xie, Wei Chen, Ting-Ting Wang, Da-Yong Gu, Peng-Wei Yan, Li Yin, Xia He

Affiliations

  1. Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing 210009, China.

PMID: 29100350 PMCID: PMC5652744 DOI: 10.18632/oncotarget.20014

Abstract

PURPOSE: The objective of this study is to evaluate the contribution of induction (IC) or adjuvant (AC) chemotherapy additional to concurrent chemoradiotherapy (CCRT) for patients with T3-4N0-1 nasopharyngeal carcinoma (NPC) in the era of intensity-modulate radiotherapy (IMRT).

METHOD AND MATERIALS: We retrospectively reviewed the data on 685 patients with newly diagnosed T3-4N0-1 NPC. Propensity score matching (PSM) method was used to match patients. Survival outcomes between different groups were calculated by Kaplan-Meier method and compared using log-rank test. Cox proportional hazard model was adopted to establish independent prognostic factors.

RESULTS: In total, 236 pairs were selected from the primary cohort. Univariate analysis revealed 3-year overall survival (OS) (90.8% vs. 90.3%,

CONCLUSION: Patients with T3-4N0-1 NPC receiving CCRT could not benefit from additional induction or adjuvant chemotherapy in the era of IMRT.

Keywords: adjuvant chemotherapy; concurrent chemoradiotherapy; induction chemotherapy; nasopharyngeal carcinoma; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no competing interest.

References

  1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  2. J Cancer. 2016 Jul 05;7(11):1465-71 - PubMed
  3. Sci Rep. 2015 Nov 13;5:16664 - PubMed
  4. J Clin Oncol. 2001 Dec 1;19(23):4305-13 - PubMed
  5. Ann Oncol. 2015 Jan;26(1):205-11 - PubMed
  6. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1342-8 - PubMed
  7. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):952-60 - PubMed
  8. Cancer. 1998 Dec 1;83(11):2270-83 - PubMed
  9. Sci Rep. 2016 Feb 29;6:22000 - PubMed
  10. Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):463-9 - PubMed
  11. Eur J Cancer. 2010 Jul;46(11):1967-78 - PubMed
  12. J Clin Oncol. 2017 Feb 10;35(5):498-505 - PubMed
  13. J Clin Oncol. 2002 Apr 15;20(8):2038-44 - PubMed
  14. J Clin Oncol. 2003 Feb 15;21(4):631-7 - PubMed
  15. Lancet Oncol. 2012 Feb;13(2):163-71 - PubMed
  16. Med Decis Making. 2009 Nov-Dec;29(6):661-77 - PubMed
  17. Lancet Oncol. 2016 Nov;17 (11):1509-1520 - PubMed
  18. J Natl Cancer Inst. 2005 Apr 6;97(7):536-9 - PubMed
  19. J Clin Oncol. 2001 Mar 1;19(5):1350-7 - PubMed
  20. J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9 - PubMed
  21. Ann Surg Oncol. 2010 Jun;17(6):1471-4 - PubMed
  22. J Clin Oncol. 2009 Jan 10;27(2):242-9 - PubMed
  23. N Engl J Med. 2004 Jun 10;350(24):2461-70 - PubMed
  24. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):161-8 - PubMed
  25. Radiother Oncol. 2014 Mar;110(3):398-403 - PubMed
  26. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):47-56 - PubMed
  27. J Clin Oncol. 1998 Apr;16(4):1310-7 - PubMed
  28. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1326-34 - PubMed
  29. Chin J Cancer. 2011 Feb;30(2):114-9 - PubMed
  30. Clin Cancer Res. 2008 Nov 15;14 (22):7497-503 - PubMed

Publication Types